Side-by-Side Comparison
AOD-9604 vs Tirzepatide: Mechanism, Evidence & Safety Compared
An evidence-based side-by-side look at how AOD-9604 and Tirzepatide differ in mechanism, regulatory status, strength of the research base, and clinical application — compiled from the published literature and the FDA regulatory record.
Educational content only. This page is compiled from published research for reference and is not medical advice, diagnosis, or treatment. Readers should verify claims against primary sources and consult a qualified healthcare provider before making any health decisions. Full disclaimer.
AOD-9604
L2Also: Advanced Obesity Drug 9604, Anti-Obesity Drug 9604, Tyr-hGH Fragment 177-191
A modified fragment of human growth hormone studied for fat metabolism without the growth-promoting effects of full GH.
Also: Mounjaro, Zepbound
An FDA-approved dual GIP/GLP-1 receptor agonist that has shown the highest weight loss results of any approved medication.
Side-by-side comparison
| Attribute | AOD-9604 | Tirzepatide |
|---|---|---|
| Primary mechanism | Lipolytic GH Fragment Activity | Dual GIP/GLP-1 Agonism |
| FDA status | Research Only | FDA Approved |
| Evidence level | Preclinical Evidence | FDA Approved |
| Human trials | Yes (1+ indexed) | Yes (50+ indexed) |
| Studies indexed | 23 total (2 human, 14 animal) | 180 total (95 human, 40 animal) |
| Primary uses researched | Fat metabolism, Weight loss | Weight management, Type 2 diabetes |
| Administration routes | oral, subcutaneous | subcutaneous |
| Molecular weight | 1815.08 Da | 4813.45 Da |
| Amino acids | 16 | 39 |
| Category | weight loss | weight loss |
| WADA status | Prohibited | Permitted |
Key differences
Mechanism. AOD-9604 acts primarily through lipolytic gh fragment activity, while Tirzepatide acts primarily through dual gip/glp-1 agonism. This means they address different biological pathways even when targeting overlapping clinical goals.
Regulatory status. AOD-9604 is classified as research only; Tirzepatide is classified as fda approved. Regulatory status drives availability, legality, and the standard of evidence required for specific therapeutic claims.
Evidence base. Tirzepatide sits at a higher evidence level (L5) than AOD-9604 (L2) under PeptideMark's L1–L5 methodology.
Research focus. Published research on AOD-9604 has concentrated on fat metabolism, weight loss. Research on Tirzepatide has concentrated on weight management, type 2 diabetes. These research programs have limited overlap, and comparisons are most useful when readers are evaluating adjacent therapeutic goals.
Safety snapshot
| Attribute | AOD-9604 | Tirzepatide |
|---|---|---|
| Documented effects | 4 total | 12 total |
| Serious events | 0 | 1 |
| Common events | 1 | 6 |
| Black box warning | No | Yes |
| Contraindications | 3 listed | 3 listed |
| Drug interactions | 2 flagged | 3 flagged |
| Most common event | Injection site reactions | Nausea |
Strengths & limitations
AOD-9604
Strengths
- Represents an area of active research interest with growing study volume
Limitations
- Not FDA-approved for any indication — research use only
- Limited evidence base (L2)
- Few human trials — most data is preclinical
- Prohibited in competitive sport under WADA
Tirzepatide
Strengths
- FDA-approved with established regulatory record
- Strong evidence base (L5)
- Multiple human clinical trials (50+ indexed)
- Substantial human study volume (95 human studies)
Limitations
- Carries an FDA black box warning
Representative studies
AOD-9604
A double blind placebo controlled study of the effects of AOD9604 in overweight and obese subjects
Stier H, et al. · Journal of Obesity & Weight Loss Therapy (2013)
AOD-9604 failed to produce statistically significant weight loss compared to placebo in a clinical trial.
AOD 9604 Promotes Cartilage Proliferation and Type II Collagen Synthesis in Osteoarthritic Chondrocytes
Wu X, Brown L, Kasran A, et al. · International Journal of Obesity (2007)
AOD 9604 increased type II collagen synthesis by 180% and cartilage proteoglycan content by 156% in human OA chondrocytes.
PubMed 17387518Tirzepatide
Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1)
Jastreboff AM, Aronne LJ, Ahmad NN, et al. · New England Journal of Medicine (2022)
Tirzepatide 15mg resulted in 22.5% mean weight loss, with 62.9% of participants achieving ≥20% weight loss — unprecedented for an approved drug.
PubMed 35658024Tirzepatide Once Weekly for the Treatment of Obesity in People with Type 2 Diabetes (SURMOUNT-2)
Garvey WT, Frias JP, Jastreboff AM, et al. · The Lancet (2023)
Tirzepatide 15mg produced clinically meaningful weight loss (14.7%) even in the harder-to-treat diabetes population with significant insulin resistance.
PubMed 37385275Frequently asked
What is the main difference between AOD-9604 and Tirzepatide?
AOD-9604 is a modified fragment of human growth hormone studied for fat metabolism without the growth-promoting effects of full gh. Its primary mechanism is lipolytic gh fragment activity. Tirzepatide is an fda-approved dual gip/glp-1 receptor agonist that has shown the highest weight loss results of any approved medication. Its primary mechanism is dual gip/glp-1 agonism. The two differ in regulatory status (Research Only vs FDA Approved), strength of evidence (L2 vs L5), and the primary conditions for which each is researched.
Is AOD-9604 or Tirzepatide FDA approved?
AOD-9604: Not FDA-approved. Has GRAS (Generally Recognized as Safe) status as a food additive only. Not approved as a drug. Tirzepatide: FDA-approved dual GIP/GLP-1 receptor agonist. Mounjaro approved for type 2 diabetes (2022). Zepbound approved for chronic weight management (2023).
How does the evidence base compare?
AOD-9604 has 23 indexed studies (2 human, 14 animal) and is rated Preclinical Evidence. Tirzepatide has 180 indexed studies (95 human, 40 animal) and is rated FDA Approved. Evidence ratings reflect PeptideMark's L1–L5 methodology based on study type, sample size, and replication.
Can AOD-9604 and Tirzepatide be compared directly?
Yes — both compounds share the weight loss category, meaning head-to-head comparisons are meaningful for the same therapeutic targets. Direct head-to-head trials between peptides are rare, however, so most comparisons rely on separate trial datasets rather than direct RCT data.
Are AOD-9604 and Tirzepatide commonly stacked together?
There is no widely documented stacking protocol combining AOD-9604 and Tirzepatide in the peer-reviewed literature. Any combination use should be supervised by a qualified clinician familiar with both compounds' pharmacology and contraindications.
Which has a better-documented safety profile, AOD-9604 or Tirzepatide?
AOD-9604 has 4 documented side effects (0 serious). Tirzepatide has 12 documented side effects (1 serious, including a black box warning). Better documentation does not necessarily mean safer — FDA-approved drugs have more rigorous adverse-event reporting, while research-only compounds may appear "cleaner" simply because fewer controlled trials have captured events systematically.
How are AOD-9604 and Tirzepatide administered?
AOD-9604 is typically administered via oral or subcutaneous. Tirzepatide is typically administered via subcutaneous. Route differences affect onset, peak levels, and patient convenience.
Which is better, AOD-9604 or Tirzepatide?
"Better" depends on the therapeutic goal, regulatory context, and individual response. AOD-9604 is most researched for fat metabolism and weight loss; Tirzepatide is most researched for weight management and type 2 diabetes. FDA status also matters: Research Only for AOD-9604 vs FDA Approved for Tirzepatide. This page is educational — any decision to use either compound should be made with a qualified clinician who has reviewed your medical history.
Related comparisons
Full profile
AOD-9604 →
Full profile
Tirzepatide →